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Atherosclerosis is an inﬂammatory process due to oxidized low-density lipoprotein (oxLDL) accu-
mulation in macrophages. We investigated the involvement of microRNAs in oxLDL accumulation
and inﬂammatory response in macrophages. The expression of miR-146a decreases under oxLDL
stimulation. MiR-146a signiﬁcantly reduces intracellular LDL cholesterol content and secretion of
interleukin 6, interleukin 8, chemokine (C–C motif) ligand 2 andmatrix metallopeptidase 9. Toll-like
receptor 4 (TLR4) is a relevant target of miR-146a, and miR-146a inhibits the activation of TLR4-
dependent intracellular signaling pathways involved in cytoskeleton rearrangement, lipid uptake,
and inﬂammatory cytokine secretion. These results indicate that miR-146a contributes to the regu-
lation of both oxLDL accumulation and inﬂammatory response by negatively regulating TLR4 and
thereby inhibiting the activation of TLR4-dependent signaling pathways. Over-expression of miR-
146a may be useful in the prevention and treatment of atherosclerosis.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Inhibition of lipid accumulation in macrophage-derived foam
cells and reduction of consequent inﬂammatory response are
crucial for preventing atherosclerotic plaque formation and
coronary lesion progression [1]. Several scavenger receptors [e.g.,chemical Societies. Published by E
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F. Shen).CD36 molecule (CD36), scavenger receptor A (SRA)] possess ability
to take up oxidized low-density lipoprotein (oxLDL) in macro-
phages, and have been linked to atherosclerotic process [2]. In ani-
mal experiments, activation of toll-like receptor 4 (TLR4) promotes
vascular lipid accumulation [3], and TLR4-dependent signal path-
ways contribute to minimally modiﬁed low-density lipoprotein
(mmLDL)-induced cytoskeleton rearrangement necessary for the
process of lipoprotein uptake [4]. Similarly, oxLDL activates TLR4,
triggering inﬂammatory response in macrophages through mito-
gen-activated protein kinase (MAPK) pathway [5].
MicroRNAs (miRNAs) inhibit transcription or translation by
interacting with 30 untranslated region (30-UTR) of a target gene
[6], and are involved in inﬂammatory process in patients with
coronary artery disease [7,8]. MiR-146a interacts directly with
interleukin-1 receptor-associated kinase 1 (IRAK1)/TNF receptor-
associated factor 6 (TRAF6), suppressing secretion of inﬂammatory
cytokines in macrophages [9,10]. Recently, miR-125-5p was
considered to partly inhibit lipid uptake by down-modulation of
oxysterol binding protein-like 9 (ORP9), and to decrease inﬂamma-
tory cytokine expression in oxLDL-stimulated monocyte-derived
macrophages [11]. However, the precise role of miRNAs in foam
cell formation and inﬂammatory response remains unclear.
In this study, we sought to investigate the differential
expression of miRNAs in oxLDL-stimulated macrophages, and tolsevier B.V. All rights reserved.
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content and inﬂammatory cytokine secretion. The interaction of
miRNA–mRNA was examined by luciferase assay, Western blot
and rescue assay, to further elucidate the potential mechanisms.Fig. 1. Analysis of differentially expressed miRNAs in non-oxLDL-stimulated (M)
and oxLDL-stimulated (MO) macrophages. The six most signiﬁcant aberrantly
expressed miRNAs were further identiﬁed by Taqman real-time PCR (n = 6).
⁄⁄P < 0.01 vs. M.2. Materials and methods
2.1. Cell culture and treatment
THP-1 cells (ATCC, VA, USA) were seeded on six-well plates at a
density of 1.0  106 cells/well and differentiated into macrophages
by administrating 100 ng/ml phorbol 12-myristate 13-acetate (Cal-
Biochem, CA, USA) for 48 h. Low-density lipoprotein was puriﬁed
to homogeneity by ultra-centrifugation, and oxidized using
20 lM cupric sulphate in PBS at 37 C for 24 h. The level of oxida-
tion was measured using TBAR determination with the malondial-
dehyde (MDA) standard, and the migration factor of oxLDL was 2.2.
Macrophages were incubated with oxLDL (50 lg/ml) for 24 h to
transform into foam cells. Hela cells (ATCC) were used in luciferase
assay.
2.2. Analysis of differential expression of miRNAs
Total RNA (2–5 lg) was extracted using Trizol reagent
(Invitrogen, CA, USA). Microarray analysis was performed using
the lParaﬂo™ miRNA system (LC Sciences, USA). Pre-miRNAs
(<300 nucleotides) were isolated and labeled with ﬂuorescent dyes
Cy3 and Cy5, and images were obtained using a laser scanner
(GenePix 4000B, Molecular Devices). Microarray data were nor-
malized with a LOWESS (locally weighted regression) ﬁlter, which
was further veriﬁed by sequence-speciﬁc primer from TaqMan
real-time polymerase chain reaction (PCR) (Applied Biosystems,
CA, USA) for six times [12] in each candidate miRNA. TaqMan miR-
NA assay kits with a stemlooped primer for reverse transcription
were used to accurately detect mature miRNAs.
2.3. Prediction of miR-146a target sites
A consensus approach employing miRanda, RNAhybrid, and
TargetScan was applied to target prediction. In addition, RNAhy-
brid with options 30-UTR_human for vertebrate sequences was uti-
lized to calculate free energies of miR-146a: TLR4 mRNA and
predicted target sites of miR-146a [13,14].
2.4. Luciferase assay
Human tlr4 cDNA, containing putative and mutant target sites
for miR-146a, was chemically synthesized and inserted into a
pMIR-REPORT™ vector (Ambion, TX, USA). The pMIR-REPORT™
b-gal control vector (Ambion) was used as a reference. For lucifer-
ase assay, Hela cells were co-transfected with wild- (pMIR-tlr4-wt)
or mutant-type (pMIR-tlr4-mt) reporter vector and miR-146a
mimics using Lipofectamine 2000 (Invitrogen). Luciferase activity
was measured 48 h after transfection using a dual-luciferase assay
kit (Promega, WI, USA) [15].
2.5. Assessment of intracellular LDL cholesterol content
Cultured and transfected macrophages were washed with PBS
(Gibco, NY, USA) and then ﬁxed in 4% paraformaldehyde/PBS for
15 min. After rinsing with ddH2O, macrophages were stained
with 0.3% oil red O (Sigma–Aldrich, MO, USA) in 60% isopropanol
for 10 min, and incubated with DiI-Ac-LDL (Invitrogen). Pictures
were taken using confocal imaging ﬂuorescence microscope
(Leica Microsystems). The DiI ﬂuorescence was analyzed usingﬂow cytometry (BD, NJ, USA) (n = 3), and the oil red O staining
was measured by OD 500 nm (n = 3). Intracellular LDL choles-
terol content was quantiﬁed using a colorimetric method and
expressed as relative value to total protein concentration
(n = 3) (Biovision, CA, USA) [16].
2.6. Quantitative real-time PCR
For macrophages transfected with miR-146a mimics or inhibi-
tors, the mRNA levels were determined after 24 h with a SYBR-
Green reagent kit (Takara, Dalian, China) [17]. The gene speciﬁc
primers used are shown in Supplementary Table 1.
2.7. Western blotting
Proteins were isolated and quantiﬁed using the BCA method
(Pierce, Rockford, IL). For each sample, 30 lg protein was loaded
onto a 10% SDS–polyacrylamide gel. After electrophoresis, protein
was transferred onto a PVDF membrane (Millipore, MA, USA) by
electro-elution. The membrane was incubated initially with TLR4,
mitogen-activated protein kinase 14 (p38), phospho-p38, mito-
gen-activated protein kinase 1 (ERK), phospho-ERK, mitogen-
activated protein kinase 8 (JNK) pan, phospho-JNK pan, nuclear
factor of kappa light polypeptide gene enhancer in B-cells 1 (NF-
jB), phospho-NF-jB, IRAK1 and TRAF6 (Cellsignaling, MA, USA)
overnight at 4 C, then with HRP-conjugated goat anti-Rabbit IgG
(Cellsignaling) for 2 h at room temperature. After washing, the
membrane was processed using Immobilon™Western chemilumi-
nescent HRP substrate (Millipore). b-Actin (Cellsignaling) was
served as internal control.
2.8. Oligonucleotide transfection
Macrophages were transfected with 100 pmol MiRIDIAN mim-
ics and 100 pmol inhibitors (Dharmacon, CO, USA), respectively,
using Lipofectamine 2000 (Invitrogen). To conﬁrm the efﬁciency
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labeled with FAM was also transfected. Small interference RNA
(siRNA) was used for knockdown of tlr4 (Dharmacon). Cells were
transfected for 48 h and exposed to oxLDL (50 lg/ml) for 24 h.
2.9. Plasmid construction and transfection
Human tlr4 cDNA was all chemically synthesized. The cDNA
fragments were cloned into pVAX1 plasmid (Invitrogen), which
was veriﬁed by sequencing. Macrophages were transfected with
combination plasmid using Lipofectamine 2000 (Invitrogen). Cells
were transfected for 48 h and exposed to oxLDL (50 lg/ml) for
24 h.
2.10. Human phosphokinase array
At 48 h after transfection with 100 pmol mimics and negative
control, macrophages were treated with oxLDL for 1 h, and total
protein was puriﬁed. Non-treated-macrophages were used as con-
trol. Cell lysates (250 mg total protein per array) were applied and
incubated with Human Phospho-Kinase Array kit (R&D Systems,
MN, USA). Gray values were quantiﬁed using NIH image software
analysis [18].Fig. 2. Effect of miR-146a on LDL cholesterol content in macrophages. (A) Pictures acqu
experiments (1200). (B) Dil ﬂuorescence intensity was analyzed using ﬂow cytometry (
vs. NC). (D) Total intracellular LDL cholesterol was determined using a colorimetric met2.11. Enzyme-linked immunosorbent assay (ELISA)
Levels of interleukin 6 (IL-6), interleukin 8 (IL-8), chemokine (C–
C motif) ligand 2 (MCP-1) and matrix metallopeptidase 9 (MMP-9)
in the supernatants of non-oxLDL-stimulated and oxLDL-stimu-
lated macrophages transfected individually with native control,
TLR4 cDNA recombination plasmid, TLR4 siRNA, miR-146a mimics
and inhibitors were measured using ELISA kits (Invitrogen).
2.12. Statistical analysis
Data are presented as means ± S.E.M., and were compared using
Student’s t-test (for two group comparisons) or analysis of variance
(>2 group comparisons) when appropriate. A P-value of <0.05 was
considered statistically signiﬁcant.
3. Results
3.1. Microarray analysis of miRNA expression
Compared with non-oxLDL-stimulated macrophages, let-7c and
miR-19b were up-regulated, but miR-146a, miR-1826, miR-132
and miR-923 were down-regulated in oxLDL-stimulated macro-ired and processed at identical conditions are representative of three independent
n = 3; ⁄P < 0.05 vs. NC). (C) Oil red O was analyzed using OD 500 nm (n = 3; ⁄P < 0.05
hod (n = 3; ⁄P < 0.05 vs. NC). NC: Cells transfected with negative control miRNAs.
Fig. 3. Veriﬁcation of target genes of miR-146a. (A) Sequence alignment and minimum free energy (MFE) of miR-146a and its targets in wild type (wt) or mutant type (mt) 30-
UTRs of TLR4. (B) MiR-146a mimics and inhibitors affected the gene expression patterns in macrophages stimulated with oxLDL (n = 3; ⁄⁄P < 0.01 vs. NC). (C) Changes of
luciferase activity by miR-146a mimic and inhibitor in 30-UTR of TLR4 (n = 3; ⁄⁄P < 0.01 vs. Hela cells not transfected with miRNAs [control]). (D) TLR4 protein levels were
analyzed with Western blot and normalized by b-actin (TLR4/b-actin; n = 3). NC: As in Fig. 2.
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normalization procedure that were signiﬁcantly different between
oxLDL-stimulated and non-oxLDL-stimulated macrophages are
listed in Supplementary Table 2.
3.2. MiRNAs affected intracellular LDL cholesterol content
Compared with negative control, the DiI-Ac-LDL ﬂuorescence,
oil red O elution and intracellular LDL cholesterol content were de-
creased in the macrophages with over-expression of miR-146a
(Fig. 2A–C), but was not altered in those transfected by let-7c
and miR-19b inhibitors as well as miR-1826, miR-132 and miR-
923 mimics (Fig. 2D). The expression of miR-146a mimics is shown
in Supplementary Fig. 1D.
3.3. MiR-146a reduced TLR4 expression in oxLDL-stimulated
macrophages
The minimum free energy of miR-146a and alignment sequence
in TLR4 30-UTR was 18.7 kcal/mol (Fig. 3A). In oxLDL-stimulated
macrophages, the expression of TLR4 as target gene was decreased
by miR-146a mimics, but the miR-146a inhibitors did not change
TLR4 expression (Fig. 3B). After co-transfecting with miR-146a
and pMIR-TLR4-wild vector, luciferase activity was decreased sig-
niﬁcantly. This effect was completely abolished by substituting this
vector with its mutant version (Fig. 3C). In oxLDL-stimulated mac-
rophages, TLR4 protein was signiﬁcantly up-regulated (Supplemen-
tary Fig. 2A). TLR4 protein was signiﬁcantly down-regulated by
transfection with miR-146a mimics, but was only slightly reduced
by miR-146a inhibitors in oxLDL-stimulated microphages
(Fig. 3D). In non-treated-macrophages, miR-146a inhibitors attenu-
ated miR-146a silencing TLR4 expression (Supplementary Fig. 2B).
The efﬁciency of oligo and plasmid transfection and the expression
of miR-146a mimics are shown in Supplementary Fig. 1A, B and D.3.4. MiR-146a decreased inﬂammatory cytokine secretion
Levels of IL-6, IL-8, MCP-1, and MMP-9 were reduced by miR-
146a with knock-down of TLR4, but increased by over-expression
of TLR4 (Fig. 4). The efﬁciency of siRNA knock-down TLR4 expres-
sion and the expression of miR-146a mimics are shown in Supple-
mentary Fig. 1C and D.
3.5. Signaling pathways regulated by miR-146a
OxLDL induced phosphorylation of v-src sarcoma (Schmidt-
Ruppin A-2) viral oncogene homolog (avian) (Src), Yes, Fyn, Fgr,
Lck, Hck, Lyn, FAK, JNK, proline-rich tyrosine kinase 2 (Pyk2), pax-
illin, p38 MAPK, ERK1/2, JNK pan and NF-jB. In contrast, miR-146a
inhibited the activation of these kinases which were induced by
ox-LDL (Fig. 5A–C) (Supplementary Tables 3 and 4). Similarly,
over-expression of miR-146a decreased the expression of IRAK1
and TRAF6 (Fig. 5D). The expression of miR-146a mimics is shown
in Supplementary Fig. 1D.
4. Discussion
This study demonstrated that miR-146a synchronously reduced
LDL cholesterol level and inﬂammatory cytokine secretion in
oxLDL-stimulated macrophages, by directly down-modulating
TLR4 and inhibiting activation of TLR4-dependent signaling
pathway.
Toll-like receptors (TLRs) play multiple roles in atherosclerosis
[19], and are highly expressed in human atherosclerotic plaques
[20]. Intracellular cholesterol content in macrophages was in-
creased by approximately ﬁve-folds following stimulation with
lipopolysaccharide (LPS) (a TLR4 ligand), which was greater than
that with Zymosan [a toll-like receptor 2 (TLR2) ligand] or polyino-
sinic:polycytidylic acid (poly I:C) [a toll-like receptor 3 (TLR3)
Fig. 4. Secretion of inﬂammatory cytokines in oxLDL-stimulated macrophages. Levels of IL-6, IL-8, MCP-1 and MMP-9 were signiﬁcantly reduced by miR-146a (n = 3;
⁄P < 0.05, ⁄⁄P < 0.01 vs. NC). NC: As in Fig. 2.
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in circulating monocytes was signiﬁcantly attenuated [21]. In this
study, TLR4 was signiﬁcantly up-regulated in oxLDL-stimulated
microphages. Compared with over-expression of TLR4, knock-
down of TLR4 resulted in a signiﬁcant reduction in intracellular
LDL cholesterol content and inﬂammatory cytokine secretion. To-
gether with previous reports that TLR4 produces a vicious circle
in oxLDL-induced pathological process in macrophages [22,23],
our observations further substantiate the concept that TLR4 is an
important mediator of foam cell formation.
In this study, with sustained oxLDL stimulation, TLR4 was up-
regulated with a decrease in expression of miR-146a. In contrast,
TLR4 was down-regulated by over-expression of miR-146a. Bioin-
formatics analysis demonstrated a possible interaction between
miR-146a and TLR4, and measurement of luciferase activity further
proved that miR-146a directly targeted TLR4. The results of rescue
assay showed that intracellular LDL cholesterol content was de-
creased by co-transfection of miR-146a with TLR4+3
0UTR, and miR-
146a signiﬁcantly reduced IL-6, IL-8, MCP-1, and MMP-9 levels in
oxLDL-stimulated macrophages. These ﬁndings suggest that the
effects of miR-146a on lipid accumulation and inﬂammatory
response may be attributed to its direct interaction with TLR4 in
macrophages. In this study, TLR4 was only slightly decreased withtransfection of miR-146a inhibitors in oxLDL-stimulated macro-
phages. This may be partly due to a less obvious effect at the pres-
ence of dominantly low level of miR-146a expression after oxLDL
stimulation. In non-treated macrophages, the level of miR-146a
was signiﬁcantly reduced by miR-146a inhibitor, which attenuated
TLR4 silencing.
The potential mechanism by which miR-146a inhibits lipid
accumulation and inﬂammatory response via TLR4 remains un-
clear. Previous studies have shown that cytoskeleton rearrange-
ment was induced by activation of TLR4-dependent spleen
tyrosine kinase (Syk) signaling pathway, leading to enhanced lipid
uptake [4]. Macrophage motility was increased by LPS (a TLR4 li-
gand) through Src and FAK [24], and macropinocytosis triggered
by oxLDL was dependent largely on Src family kinases and JNK
[25]. Fitzer-Attas et al. found that formation of actin cups and
cytoskeleton rearrangement were delayed in hck/ fgr/ lyn/
macrophages [26]. Hazeki et al. observed that LPS induced tyrosine
phosphorylation of Pyk2 and its substrate paxillin (an integrin-
associated focal adhesion adaptor protein), whereas PP2 (an inhib-
itor of Src family kinases) prevented TLR-induced phosphorylation
of Pyk2 and paxillin [27]. In this study, oxLDL-induced
phosphorylation of Src family kinases (Yes, Fyn, Fgr, Lck, Hck, and
Lyn), FAK and JNK was signiﬁcantly inhibited by miR-146a,
Fig. 5. Regulation of TLR4 signal pathway by miR-146a. (A) Phospho-kinase array for oxLDL-stimulated macrophages transfected with negative control miRNAs (NC) or miR-
146a mimics. Non-oxLDL-stimulated macrophages were used as control (Plates A and B were incubated with 300 lg of cell lysate). (B) Protein proﬁling in the array was
presented as pixel density. (C) Cell lysates were probed for phosphorylated p38, ERK, JNK pan and NF-jB, and the results were expressed in relative units (phosphorylated
protein/total protein, n = 3). M: Non-oxLDL-stimulated macrophages; MO: oxLDL-stimulated macrophages; MAO: oxLDL-stimulated macrophages transfected with miR-
146a. (D) TRAF6 and IRAK1 protein levels were analyzed with Western blot and normalized by b-actin (TRAF6 or IRAK1/b-actin; n = 3). Non-oxLDL-stimulated macrophages
were used as control.
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in macrophages. These results highlight that miR-146a may inhibit
cytoskeleton rearrangement and lipid uptake by blockade of TLR4–
Src–FAK–JNK axis and inhibition of phosphorylation of Pyk2 and
paxillin.
TLR4 plays a crucial role in inﬂammatory response in macro-
phages [10,28]. In this study, the secretion of inﬂammatory cyto-
kines (IL-6, IL-8, MCP-1, and MMP-9) by oxLDL stimulation was
dramatically inhibited with knock-down of TLR4 and over-expres-
sion of miR-146a, suggesting that miR-146a may regulate inﬂam-
matory response through interacting with TLR4. Lee et al. have
shown that saturated and polyunsaturated fatty acids reciprocally
modulate the activation of TLR4 and its downstream signaling
pathways involving myeloid differentiation primary response gene
(88) (MyD88)/IRAK/TRAF6 and PI3K/v-akt murine thymoma viral
oncogene homolog 1 (AKT) [29]. Taganov et al. found that miR-
146a interacts directly with IRAK1/TRAF6 in the TLR signaling
pathway, which also suppresses the secretion of inﬂammatory
cytokines [9]. In the present study, expression of TRAF6 and IRAK1
as well as TLR4 was down-regulated and phosphorylation of Akt
was inhibited by miR-146a. Likewise, oxLDL-induced NF-jB activa-
tion was offset by over-expression of miR-146a. These results
support a notion that miR-146a attenuates inﬂammatory response
in macrophages by simultaneously blocking TLR4–TRAF6–IRAK1
and TLR4–Akt pathways [30,31]. Moreover, in agreement with
previous reports that oxLDL could selectively activate p38 MAPK
[32], we also observed that oxLDL stimulation resulted in astronger activation of p38 MAPK relative to JNK and ERK1/2,
whereas miR-146a dynamically inhibited the activation of p38
MAPK, JNK and ERK1/2, which have been involved in the inﬂam-
matory process following TLR4 activation [33]. Taken together, de-
spite multiple mechanisms, TLR4 remains an important upstream
target of miR-146a.
In conclusion, this study indicates that miR-146a synchronously
inhibits oxLDL-induced foam cell formation and inﬂammatory re-
sponse in macrophages by directly targeting TLR4 and inhibiting
activation of TLR4-dependent signaling pathways. The beneﬁcial
clinical effects of over-expression of miR-146a in the prevention
and treatment of atherosclerosis deserve further investigations.
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